Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer - Wikidata - awgldk - TriplyDB

Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer

Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer

http://www.wikidata.org/entity/Q35234584

about

An integrative proteomics and interaction network-based classifier for prostate cancer diagnosis Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer.Evidence for molecular differences in prostate cancer between African American and Caucasian men Single-cell genetic analysis reveals insights into clonal development of prostate cancers and indicates loss of PTEN as a marker of poor prognosis.Investigation of miR-21, miR-141, and miR-221 expression levels in prostate adenocarcinoma for associated risk of recurrence after radical prostatectomy.Multi-transcript profiling in archival diagnostic prostate cancer needle biopsies to evaluate biomarkers in non-surgically treated men.GSTP1 promoter methylation is associated with recurrence in early stage prostate cancer.Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients.Differentially Expressed Genes and Signature Pathways of Human Prostate Cancer.Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization.Personalized management in low-risk prostate cancer: the role of biomarkers.Integrative analyses reveal a long noncoding RNA-mediated sponge regulatory network in prostate cancer Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high-grade prostatic intraepithelial neoplasia.A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumour progression.Molecular markers to guide primary radical treatment selection in localized prostate cancer.Biomarkers in prostate cancer: new era and prospective.Prognostic and predictive biomarkers in prostate cancer.Molecular biomarkers to guide precision medicine in localized prostate cancer.DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer.Recent advances in prostate cancer pathology: Gleason grading and beyond.Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH.Tumor-derived CXCL8 signaling augments stroma-derived CCL2-promoted proliferation and CXCL12-mediated invasion of PTEN-deficient prostate cancer cells.PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer.Androgen deprivation leads to increased carbohydrate metabolism and hexokinase 2-mediated survival in Pten/Tp53-deficient prostate cancer.Low Intratumoral Mast Cells Are Associated With a Higher Risk of Prostate Cancer Recurrence.Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer.Exploring prostate cancer genome reveals simultaneous losses of PTEN, FAS and PAPSS2 in patients with PSA recurrence after radical prostatectomy.PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas.The role of androgen receptor expression in the curative treatment of prostate cancer with radiotherapy: a pilot study Molecular markers for prostate cancer in formalin-fixed paraffin-embedded tissues.Cancer Prognosis Defined by the Combined Analysis of 8q, PTEN and ERG.PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort.Metformin Attenuates Testosterone-Induced Prostatic Hyperplasia in Rats: A Pharmacological Perspective.PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy.Utility of PTEN and ERG immunostaining for distinguishing high-grade PIN from intraductal carcinoma of the prostate on needle biopsy.PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer.Prostate cancer: towards appropriate use of androgen deprivation therapy.Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma.

P2860

Q28533442-BC7848B0-730A-41A6-8E65-87F720D4F28E Q30573750-88D90FFA-A229-498C-81D3-CD5F0C8A3378 Q34205227-7E30F93E-8F02-4CE5-8ABF-9A540EDF9E2A Q34302881-236ADBBB-AFD2-4222-A507-23151C6BB8D9 Q34381845-1DD7CCA1-AC32-46C4-946A-36A55BD782F5 Q35256915-10F2B146-4598-47E9-B33B-D94969DFC95B Q35322421-92D2AD2B-B6F4-43A5-9675-448BFD77B197 Q35690915-FA4A6916-ED88-4C53-9472-7C4DA99E8159 Q35873154-28292FBF-0308-49C4-9D05-4842D35B4CA9 Q36469889-E63D48BF-63B9-4CC3-BBB0-9F6777B5D83E Q36495701-EF326174-6DC9-4A26-81E5-249312A3519A Q36698824-8B2C09E4-9C79-4CEC-B4C0-30BFB446463D Q36724548-EF377133-32AE-4AFB-A9D8-7782F00E586B Q36887707-C6B2439D-2EA6-4979-8B92-0018846DF83D Q37690429-62CDC94E-6A9A-40C4-9F11-569817CD47E4 Q38226242-FA220FA2-D66C-4C3A-85E1-D6DCCDF39ACF Q38232466-75D027E3-17A0-435D-88F8-A005833D59CA Q38628081-2212626F-7AB5-4305-8119-EC6FA5F604F8 Q38668635-0D640E45-0F1B-40D1-9AAF-A0B88016037C Q38774228-E41585F9-6D8C-45CD-97AB-D5D6FAA75003 Q38779933-E132FC61-67E0-44B9-A095-236680DBB967 Q38833458-A059A36E-DC70-436E-A271-C9C153CD3088 Q38980564-9621139E-4814-444A-8534-30DB359CA2E4 Q39401816-712451CB-87F2-4091-B2D4-AA778CDDF0C0 Q39634850-11165CEE-27C4-429C-B893-D426E0543A69 Q40465162-DA6B81B7-1446-4650-8ED3-84260F049EE6 Q40740686-AC1366F6-F9A7-4D09-87A1-05A4D3021DC8 Q40978920-9395180D-5385-4F89-86AD-26E7B4676DF9 Q41439657-7A0C78C0-9CE4-4F2A-B9B6-3D4465320263 Q41907553-5186917C-E6EE-40EB-A9F7-CD7536177180 Q41963995-4D5EDDB6-D58D-4666-AA37-1E4244F60CFD Q42184292-287F1867-03FC-4DD5-B75A-ABF783301621 Q42356687-5EAD79E5-FDC9-431C-98D5-15033C427643 Q42371556-60F81752-ED33-4E90-BD4E-65C0778C7C11 Q42700323-6BB24BD5-4E80-4282-AA42-97585F50E0F2 Q43089446-F8BD16B4-0700-4ACB-BD41-7E8A5220CF73 Q43104641-AF68BDE2-F6BB-46AA-B152-0C78BC5052DE Q45251986-0950FCD5-2B4F-4636-81D2-0F980B4654F7 Q45371478-16CD41AC-778F-419D-A796-61218BD284CC Q45968823-79AE7C1B-0ED1-4802-A3E0-31BAEBA50F58

P2860

Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer

http://www.wikidata.org/entity/Q35234584

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Loss of PTEN expression is ass ...... ally localized prostate cancer

@ast

Loss of PTEN expression is ass ...... ally localized prostate cancer

@en

type

label

Loss of PTEN expression is ass ...... ally localized prostate cancer

@ast

Loss of PTEN expression is ass ...... ally localized prostate cancer

@en

prefLabel

Loss of PTEN expression is ass ...... ally localized prostate cancer

@ast

Loss of PTEN expression is ass ...... ally localized prostate cancer

@en

P1433

Q35234584-8B666D06-27A8-4C0D-86E5-111B8982E7DD

P1476

Q35234584-C76B8348-5EA1-4934-8472-EEAA229FDAC1

P2093

Q35234584-0EBE7B4F-64D7-4BA2-B07A-789A88333CBC

Q35234584-13DE7F63-0A5A-4DCA-857B-EA395A8D1E5F

Q35234584-1E4C753E-282D-488E-93D4-D8D0BE6B7295

Q35234584-37461CE0-C3AE-4B40-9CF4-04DE4E56AE6E

Q35234584-711C985A-D950-4044-9E0E-885C4AA8B66D

Q35234584-9634B783-5601-47C9-99BC-B363D7D020CE

Q35234584-98FFB6BC-F8BC-4CDB-BC27-7738E1D32C4B

Q35234584-DE58A12A-871A-4715-A80F-EE1D82EC0F32

Q35234584-DEB106C0-7E6B-4798-88FD-949BE8224BD0

P2860

Q35234584-06BEAA84-A735-4F15-98DC-4FE62831D78D

Q35234584-0C20DB9E-C345-4159-B309-8B12CB86B191

Q35234584-1B27B9AF-7CE5-473B-8CFF-313AA7851E7C

Q35234584-2F353C69-B1CD-4D6F-AABC-DB0D8811DF47

Q35234584-3D889073-25B0-4C8E-AFF4-1369FF1D22EF

Q35234584-55535189-F920-423D-AF64-5B228F510F16

Q35234584-638A19B3-F18C-4D56-85CA-393760E45707

Q35234584-64F42984-A021-4204-9601-FEFD4B1569F3

Q35234584-94252DF7-1D30-4DCE-93C5-ED4925D317CC

Q35234584-94AE7F7E-3CD2-43AD-ACCD-5DA1BA329D31

P2888

Q35234584-0DB062BD-869B-4F62-A90A-99AB6D985161

P304

Q35234584-7ECCBB4A-0C67-4DCE-BA68-4A298FE5F495

P31

Q35234584-EF992FE3-9169-4FFD-B4DE-74F74FDB8AF5

P356

Q35234584-47448D13-C2E2-4EE6-9DF3-D7FC98D32353

P433

Q35234584-065995F1-BE2A-4BBB-9278-F24F48DEDA50

P478

Q35234584-3AE0CAE6-626A-4137-B1E5-87883A21E201

P577

Q35234584-ED76BF10-4194-4356-8BC5-32D5237E8980

P5875

Q35234584-036A0259-4CDD-405C-AA4A-59581FECFE24

P6179

Q35234584-16A31251-5009-4F73-886C-DB03A003032B

P698

Q35234584-5CA1CE74-E6E0-44CF-A2DC-8C05DE8F9544

P932

Q35234584-2ACFC78F-E1AB-4BFA-9C0D-81E91AE9BB1D

P356

MODPATHOL.2012.104

P1433

Modern Pathology

P1476

Loss of PTEN expression is ass ...... ally localized prostate cancer

@en

P2093

Alcides Chaux

http://www.w3.org/2001/XMLSchema#string

Angelo M De Marzo

http://www.w3.org/2001/XMLSchema#string

Elizabeth A Platz

http://www.w3.org/2001/XMLSchema#string

George J Netto

http://www.w3.org/2001/XMLSchema#string

Jessica Hicks

http://www.w3.org/2001/XMLSchema#string

Luciana Schultz

http://www.w3.org/2001/XMLSchema#string

Nilda Gonzalez-Roibon

http://www.w3.org/2001/XMLSchema#string

Roula Albadine

http://www.w3.org/2001/XMLSchema#string

Sarah B Peskoe

http://www.w3.org/2001/XMLSchema#string

P2860

Pten dose dictates cancer progression in the prostate

FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.

Practical methods for tissue microarray construction.

Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.

Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth.

Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model

Pten inactivation and the emergence of androgen-independent prostate cancer.

Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression.

PTEN level in tumor suppression: how much is too little?

Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage.

P2888

modpathol.2012.104

P304

1543-1549

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MODPATHOL.2012.104

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225286863

http://www.w3.org/2001/XMLSchema#string

P6179

1047091303

http://www.w3.org/2001/XMLSchema#string

P698

22684219

http://www.w3.org/2001/XMLSchema#string

P932

4380219

http://www.w3.org/2001/XMLSchema#string